259 related articles for article (PubMed ID: 16203176)
1. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment.
Hourfar MK; Schmidt M; Seifried E; Roth WK
Vox Sang; 2005 Aug; 89(2):71-6. PubMed ID: 16101686
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
Kleinman SH; Glynn SA; Lee TH; Tobler L; Montalvo L; Todd D; Kiss JE; Shyamala V; Busch MP;
Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
[TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.
Koppelman MH; Cuijpers HT; Wessberg S; Valkeajärvi A; Pichl L; Schottstedt V; Saldanha J
Transfusion; 2012 Jul; 52(7):1498-508. PubMed ID: 22587637
[TBL] [Abstract][Full Text] [Related]
6. [Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience].
Petermann R; Piquet Y; Lapeyre M; Goujon N; Gauthier M; Lalanne V; Mouillot L; Tissier MH; Boiron JM
Transfus Clin Biol; 2010 Apr; 17(2):54-62. PubMed ID: 20674438
[TBL] [Abstract][Full Text] [Related]
7. Magnetic bead technology in viral RNA and DNA extraction from plasma minipools.
Pichl L; Heitmann A; Herzog P; Oster J; Smets H; Schottstedt V
Transfusion; 2005 Jul; 45(7):1106-10. PubMed ID: 15987354
[TBL] [Abstract][Full Text] [Related]
8. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
[TBL] [Abstract][Full Text] [Related]
9. [Parvovirus B19 DNA testing in Polish blood donors, 2004-2010].
Grabarczyk P; Korzeniowska J; Liszewski G; Kalińska A; Sulkowska E; Krug-Janiak M; Kopacz A; Łetowska M; Brojer E
Przegl Epidemiol; 2012; 66(1):7-12. PubMed ID: 22708291
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the prevalence of human parvovirus B19 DNA in Korean plasmapheresis donors.
Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS
Korean J Lab Med; 2010 Feb; 30(1):58-64. PubMed ID: 20197724
[TBL] [Abstract][Full Text] [Related]
11. Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays.
Koppelman MH; Rood IG; Fryer JF; Baylis SA; Cuypers HT
Vox Sang; 2007 Oct; 93(3):208-15. PubMed ID: 17845257
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of hepatitis A virus and parvovirus B19 in source-plasma donors and whole blood donors in China.
Han T; Li C; Zhang Y; Wang Y; Wu B; Ke L; Liu G; Li L; Liu Y; Liu Z
Transfus Med; 2015 Dec; 25(6):406-10. PubMed ID: 26564017
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.
Baylis SA; Shah N; Minor PD
J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture.
Müller MM; Fraile MI; Hourfar MK; Peris LB; Sireis W; Rubin MG; López EM; Rodriguez GT; Seifried E; Saldanha J; Schmidt M
Vox Sang; 2013 Jan; 104(1):19-29. PubMed ID: 23252689
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective "in-house" real-time PCR assay.
Daniel HD; Fletcher JG; Chandy GM; Abraham P
Indian J Med Microbiol; 2009; 27(2):111-5. PubMed ID: 19384032
[TBL] [Abstract][Full Text] [Related]
16. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction.
Klein RM; Jiang H; Niederacher D; Adams O; Du M; Horlitz M; Schley P; Marx R; Lankisch MR; Brehm MU; Strauer BE; Gabbert HE; Scheffold T; Gülker H
Z Kardiol; 2004 Apr; 93(4):300-9. PubMed ID: 15085375
[TBL] [Abstract][Full Text] [Related]
17. Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions.
Compston LI; Sarkobie F; Li C; Candotti D; Opare-Sem O; Allain JP
J Virol Methods; 2008 Jul; 151(1):47-54. PubMed ID: 18479760
[TBL] [Abstract][Full Text] [Related]
18. Blood donor screening for parvovirus B19 in Germany and Austria.
Schmidt M; Themann A; Drexler C; Bayer M; Lanzer G; Menichetti E; Lechner S; Wessin D; Prokoph B; Allain JP; Seifried E; Hourfar MK
Transfusion; 2007 Oct; 47(10):1775-82. PubMed ID: 17714425
[TBL] [Abstract][Full Text] [Related]
19. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.
Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP
Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589
[TBL] [Abstract][Full Text] [Related]
20. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients.
Jordan J; Tiangco B; Kiss J; Koch W
Vox Sang; 1998; 75(2):97-102. PubMed ID: 9784661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
